Jai Bharat Sharma
Research Subjects
Jai Bharat Sharma has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Kunal Mahajan
Himachal Heart Institute Mandi Himachal Pradesh India
5 shared publications Atul Kaushik
Department of Cardiology AIIMS Jodhpur Jodhpur India
4 shared publications- Rahul Choudhary
Department of Cardiology, All India Institute of Medical Sciences – Jodhpur, Jodhpur, India
4 shared publications - Surender Deora
Department of Cardiology, All India Institute of Medical Sciences, Jodhpur, India
4 shared publications - Surender Himral
Department of Cardiology, Himachal Heart Institute, Mandi, Himachal Pradesh, India
4 shared publications Deep Dutta
Cedar Super Specialty Clinic, Dwarka, New Delhi, India (Dutta)
2 shared publications
Latest Publications
- 17 July 2026
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 26, 1-17
Safety and Efficacy of Ticagrelor with Aspirin DAPT vs. Aspirin Alone in Patients Undergoing CABG Following ACS: A Systematic Review and Meta-Analysis
Background: It remains uncertain whether Dual Antiplatelet Therapy (DAPT) or aspirin alone is better for patients following Coronary Artery Bypass Grafting (CABG) post-Acute Coronary Syndrome (ACS). Currently available Systematic Reviews and Meta-Analyses (SRMA) are limited to the analysis of different combinations of DAPT across various clinical conditions of cardiovascular disease and are not restricted to CABG post-ACS. This SRMA aimed to evaluate the safety and efficacy of Ticagrelor with Aspirin (TA) versus aspirin alone in patients who underwent CABG following ACS. Methods: Electronic databases were searched for studies involving patients who underwent CABG after ACS and received TA in the intervention arm versus aspirin in the control arm. The primary outcomes were death and major bleeding. The secondary outcomes were Composite Cardiovascular Outcomes (CCO), Myocardial Infarction (MI), stroke, saphenous vein graft patency, revascularization, and side effects. Results: Data from five studies (4 RCTs and one cohort study; 9,659 patients) were analysed. The risk of death [OR 1.18 (95% CI 0.60-2.28); P =0.63; I²=46%] and major bleeding [OR 1.65 (95% CI 0.95-2.86); P =0.07; I²=44%] was numerically higher with TA than with aspirin alone, although these differences were not statistically significant. Composite cardiovascular outcomes [OR 0.96 (95% CI 0.74-1.24); P=0.74; I²=0%], myocardial infarction [OR 0.99 (95% CI 0.67- 1.46); P =0.94; I²=0%], stroke [OR 0.60 (95% CI 0.33-1.08); P =0.09; I²=0%], saphenous vein graft patency [OR 1.75 (95% CI 0.93-3.27); P =0.08; I²=75%], and revascularisation [OR 1.21 (95% CI 0.46-3.15); P =0.70; I²=49%] were similar between the two groups. Discussion: These findings suggest that the theoretical advantage of intensified platelet inhibition with ticagrelor-based DAPT does not translate into improved clinical outcomes in patients undergoing CABG after ACS. The pathophysiology of graft failure, which is often driven by technical factors and progressive atherosclerosis rather than platelet-mediated thrombosis alone, may partly explain the absence of additional benefit from potent dual antiplatelet therapy. At the same time, the observed numerical increase in bleeding events highlights the potential trade-off associated with more aggressive platelet inhibition in the postoperative setting. Conclusion: In patients undergoing CABG following ACS, ticagrelor-aspirin DAPT does not confer significant improvement in ischemic outcomes compared with aspirin monotherapy and may increase bleeding risk. Aspirin alone appears to provide comparable protection, supporting its continued role as the cornerstone of antiplatelet therapy after surgical revascularization. Nevertheless, antiplatelet therapy after CABG should be individualised according to each patient’s ischaemic/thrombotic and bleeding risk rather than applied uniformly
- 17 July 2026
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 26, 1-17
Safety and Efficacy of Ticagrelor with Aspirin DAPT vs. Aspirin Alone in Patients Undergoing CABG Following ACS: A Systematic Review and Meta-Analysis
Background: It remains uncertain whether Dual Antiplatelet Therapy (DAPT) or aspirin alone is better for patients following Coronary Artery Bypass Grafting (CABG) post-Acute Coronary Syndrome (ACS). Currently available Systematic Reviews and Meta-Analyses (SRMA) are limited to the analysis of different combinations of DAPT across various clinical conditions of cardiovascular disease and are not restricted to CABG post-ACS. This SRMA aimed to evaluate the safety and efficacy of Ticagrelor with Aspirin (TA) versus aspirin alone in patients who underwent CABG following ACS. Methods: Electronic databases were searched for studies involving patients who underwent CABG after ACS and received TA in the intervention arm versus aspirin in the control arm. The primary outcomes were death and major bleeding. The secondary outcomes were Composite Cardiovascular Outcomes (CCO), Myocardial Infarction (MI), stroke, saphenous vein graft patency, revascularization, and side effects. Results: Data from five studies (4 RCTs and one cohort study; 9,659 patients) were analysed. The risk of death [OR 1.18 (95% CI 0.60-2.28); P =0.63; I²=46%] and major bleeding [OR 1.65 (95% CI 0.95-2.86); P =0.07; I²=44%] was numerically higher with TA than with aspirin alone, although these differences were not statistically significant. Composite cardiovascular outcomes [OR 0.96 (95% CI 0.74-1.24); P=0.74; I²=0%], myocardial infarction [OR 0.99 (95% CI 0.67- 1.46); P =0.94; I²=0%], stroke [OR 0.60 (95% CI 0.33-1.08); P =0.09; I²=0%], saphenous vein graft patency [OR 1.75 (95% CI 0.93-3.27); P =0.08; I²=75%], and revascularisation [OR 1.21 (95% CI 0.46-3.15); P =0.70; I²=49%] were similar between the two groups. Discussion: These findings suggest that the theoretical advantage of intensified platelet inhibition with ticagrelor-based DAPT does not translate into improved clinical outcomes in patients undergoing CABG after ACS. The pathophysiology of graft failure, which is often driven by technical factors and progressive atherosclerosis rather than platelet-mediated thrombosis alone, may partly explain the absence of additional benefit from potent dual antiplatelet therapy. At the same time, the observed numerical increase in bleeding events highlights the potential trade-off associated with more aggressive platelet inhibition in the postoperative setting. Conclusion: In patients undergoing CABG following ACS, ticagrelor-aspirin DAPT does not confer significant improvement in ischemic outcomes compared with aspirin monotherapy and may increase bleeding risk. Aspirin alone appears to provide comparable protection, supporting its continued role as the cornerstone of antiplatelet therapy after surgical revascularization. Nevertheless, antiplatelet therapy after CABG should be individualised according to each patient’s ischaemic/thrombotic and bleeding risk rather than applied uniformly
- Open Access
- 26 March 2026
- Published by Springer Nature in Cureus
- Vol. 18 (3)
Transcatheter Interventions in Infants With Congenital Heart Disease: A Two-Year Retrospective Case Series From a Tertiary Centre in India
Background: Severe forms of congenital heart disease (CHD) remain a leading cause of neonatal morbidity and mortality. In recent decades, transcatheter interventions have emerged as a less invasive, repeatable, and effective alternative to surgical treatment, particularly for critically ill neonates. Objective: This retrospective study evaluates the demographic characteristics, diagnoses, procedures, complications, and 30-day outcomes of infants undergoing transcatheter interventions for CHD at Geetanjali Medical College and Hospital, Udaipur, Rajasthan, between December 2021 and November 2023. Methods: Of 108 infants admitted with CHD during the study period, 28 underwent transcatheter interventions. Patients managed surgically or medically, or whose parents declined intervention, were excluded. Results: Transcatheter interventions were successfully performed in 28 infants with CHD over two years (2021-2023). Acyanotic CHD (n = 9) included seven patent ductus arteriosus (PDA) and two ventricular septal defect (VSD) device closures (median age = 11 months, median weight = 6 kg) with 100% procedural success and 30-day survival. Patients with obstructive CHD (n = 5) underwent balloon pulmonary valvotomy and coarctoplasty (median age = 5 months, median weight = 5.6 kg), achieving universal success and 100% 30-day survival. Patients with cyanotic CHD (n = 14) received balloon atrial septostomy (n = 5), right ventricular outflow tract stenting (n = 2), and PDA stenting (n = 7) with 93% success; one PDA stenting failure occurred alongside two cases of arrhythmias, with 50% 30-day survival cumulatively. Conclusion: Transcatheter interventions are a potentially valuable modality for safe and effective definitive or bridge to definitive treatment of infants with CHD, especially in resource-limited settings. These procedures may play a vital role in bridging the gap in paediatric cardiac care.
- 26 March 2026
- Published by Springer Nature in Cureus
- Vol. 18 (3)
Open AccessTranscatheter Interventions in Infants With Congenital Heart Disease: A Two-Year Retrospective Case Series From a Tertiary Centre in India
Background: Severe forms of congenital heart disease (CHD) remain a leading cause of neonatal morbidity and mortality. In recent decades, transcatheter interventions have emerged as a less invasive, repeatable, and effective alternative to surgical treatment, particularly for critically ill neonates. Objective: This retrospective study evaluates the demographic characteristics, diagnoses, procedures, complications, and 30-day outcomes of infants undergoing transcatheter interventions for CHD at Geetanjali Medical College and Hospital, Udaipur, Rajasthan, between December 2021 and November 2023. Methods: Of 108 infants admitted with CHD during the study period, 28 underwent transcatheter interventions. Patients managed surgically or medically, or whose parents declined intervention, were excluded. Results: Transcatheter interventions were successfully performed in 28 infants with CHD over two years (2021-2023). Acyanotic CHD (n = 9) included seven patent ductus arteriosus (PDA) and two ventricular septal defect (VSD) device closures (median age = 11 months, median weight = 6 kg) with 100% procedural success and 30-day survival. Patients with obstructive CHD (n = 5) underwent balloon pulmonary valvotomy and coarctoplasty (median age = 5 months, median weight = 5.6 kg), achieving universal success and 100% 30-day survival. Patients with cyanotic CHD (n = 14) received balloon atrial septostomy (n = 5), right ventricular outflow tract stenting (n = 2), and PDA stenting (n = 7) with 93% success; one PDA stenting failure occurred alongside two cases of arrhythmias, with 50% 30-day survival cumulatively. Conclusion: Transcatheter interventions are a potentially valuable modality for safe and effective definitive or bridge to definitive treatment of infants with CHD, especially in resource-limited settings. These procedures may play a vital role in bridging the gap in paediatric cardiac care.
- Open Access
- 19 September 2025
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 29 (9) , 779
Comment on “Spectrum and Outcome of Acute Kidney Injury in Nonsurgical Cardiac Intensive Care Unit Patients: A Prospective Observational Study”
- 19 September 2025
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 29 (9) , 779
Open AccessComment on “Spectrum and Outcome of Acute Kidney Injury in Nonsurgical Cardiac Intensive Care Unit Patients: A Prospective Observational Study”
- Open Access
- 19 September 2025
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 29 (9) , 781
Hidden Constraints: Addressing Unreported Limitations in Plasmapheresis Studies for Hypertriglyceridemia-associated Pancreatitis
- 19 September 2025
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 29 (9) , 781
Open AccessHidden Constraints: Addressing Unreported Limitations in Plasmapheresis Studies for Hypertriglyceridemia-associated Pancreatitis
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 14 (1) , 130-131
Response to Letter Regarding Article, Statins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction?
Sharma JB, et al. J Lipid Atheroscler. 2025 Jan;14(1):130-131. https://doi.org/10.12997/jla.2025.14.1.130
- 1 January 2025
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 14 (1) , 130-131
Open AccessResponse to Letter Regarding Article, Statins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction?
Sharma JB, et al. J Lipid Atheroscler. 2025 Jan;14(1):130-131. https://doi.org/10.12997/jla.2025.14.1.130
- 7 June 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 18 (5) , e867-e872
Rapid achievement of low-density lipoprotein cholesterol goals within 1 month after acute coronary syndrome during combination therapy with rosuvastatin, ezetimibe and bempedoic acid: Initial experience from the LAI-REACT study
- 7 June 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 18 (5) , e867-e872
Rapid achievement of low-density lipoprotein cholesterol goals within 1 month after acute coronary syndrome during combination therapy with rosuvastatin, ezetimibe and bempedoic acid: Initial experience from the LAI-REACT study
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 13 (1) , 61-68
Statins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction?
Patel R, et al. J Lipid Atheroscler. 2024 Jan;13(1):61-68. https://doi.org/10.12997/jla.2024.13.1.61
- 1 January 2024
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 13 (1) , 61-68
Open AccessStatins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction?
Patel R, et al. J Lipid Atheroscler. 2024 Jan;13(1):61-68. https://doi.org/10.12997/jla.2024.13.1.61
- 12 January 2022
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 279 (6) , 3013-3019
Assessment of preoperative and postoperative cardiac function in children with adenotonsillar hypertrophy: a prospective cohort study
Purpose Chronic upper airway obstruction caused by adenotonsillar hypertrophy is one of the major cause of morbidity in children. It can lead to Obstructive Sleep Apnoea Syndrome, Pulmonary Hypertension, Cor Pulmonale and right heart failure. The study aimed to evaluate and compare various parameters of cardiac function with the help of echocardiography preoperatively and postoperatively in children undergoing adenotonsillectomy. Methodology A prospective cohort study was conducted on 23 patients at an apex care institute, under the age group of 4–12 years, who were diagnosed with adenotonsillar hypertrophy. Preoperative symptom analysis and Echocardiographic examination were done. After the assessment, all patients underwent surgery in the form of adenotonsillectomy. Follow-up symptom analysis and echocardiographic examination was done after 3 months postoperatively. Results Significant improvement in the obstructive symptoms were noted in postoperative group as expected (p = < 0.001) and also in parameters such as mPAP (p = < 0.001), TAPSE (p = < 0.001), TAV (p = 0.001), Ejection fraction (p = 0.027) and RVMPI (p = 0.044) were improved in postoperative group. 4 patients had Grade 1 Right ventricular diastolic dysfunction, which disappeared in three patients postoperatively. Conclusion We have concluded that there can be subclinical cardiac dysfunctions which occurs as a result of chronic upper airway obstruction due to untreated adenotonsillar hypertrophy. Routine cardiac screening in children presenting with sleep disordered breathing associated with adenotonsillar hypertrophy may be helpful in identifying and preventing the development of cardiopulmonary complication. These changes can be reversed by performing adenotonsillectomy.
- 12 January 2022
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 279 (6) , 3013-3019
Assessment of preoperative and postoperative cardiac function in children with adenotonsillar hypertrophy: a prospective cohort study
Purpose Chronic upper airway obstruction caused by adenotonsillar hypertrophy is one of the major cause of morbidity in children. It can lead to Obstructive Sleep Apnoea Syndrome, Pulmonary Hypertension, Cor Pulmonale and right heart failure. The study aimed to evaluate and compare various parameters of cardiac function with the help of echocardiography preoperatively and postoperatively in children undergoing adenotonsillectomy. Methodology A prospective cohort study was conducted on 23 patients at an apex care institute, under the age group of 4–12 years, who were diagnosed with adenotonsillar hypertrophy. Preoperative symptom analysis and Echocardiographic examination were done. After the assessment, all patients underwent surgery in the form of adenotonsillectomy. Follow-up symptom analysis and echocardiographic examination was done after 3 months postoperatively. Results Significant improvement in the obstructive symptoms were noted in postoperative group as expected (p = < 0.001) and also in parameters such as mPAP (p = < 0.001), TAPSE (p = < 0.001), TAV (p = 0.001), Ejection fraction (p = 0.027) and RVMPI (p = 0.044) were improved in postoperative group. 4 patients had Grade 1 Right ventricular diastolic dysfunction, which disappeared in three patients postoperatively. Conclusion We have concluded that there can be subclinical cardiac dysfunctions which occurs as a result of chronic upper airway obstruction due to untreated adenotonsillar hypertrophy. Routine cardiac screening in children presenting with sleep disordered breathing associated with adenotonsillar hypertrophy may be helpful in identifying and preventing the development of cardiopulmonary complication. These changes can be reversed by performing adenotonsillectomy.
- 1 November 2020
- Published by Wiley in Echocardiography
- Vol. 37 (12) , 2010-2017
Diagnostic utility of mitral annular displacement by speckle tracking echocardiography in predicting significant coronary artery disease in suspected chronic stable angina pectoris
Background More than 50% of patients currently referred for coronary angiography (CAG) with suspected chronic stable angina pectoris (CSAP) shows normal or nonobstructive CAD. Mitral annular displacement (MAD) is a function of global shortening deformation of left ventricle (LV) and mirrors sub‐endocardial ischemia in CAD. The aim of this study was to ascertain if MAD can predict the presence of CAD in patient presenting with suspected CSAP. Methods This cross‐sectional study was conducted on patients with suspected CSAP (n = 140) and preserved LV function without apparent wall motion abnormalities during the study period. We excluded patients with prior heart disease (valvular, ischemic), presenting with acute coronary syndrome, arrhythmia, heart failure, and poor imaging. All the patients were subjected to speckle tracking echocardiography (STE) and CAG. Average MAD and normalized MAD were calculated by automated function imaging (AFI), and receiver operating characteristic (ROC) curve was plotted for presence of significant CAD considering CAG as gold standard. Results The results showed that both average MAD (4 segment) and normalized MAD were significantly reduced (P = <.001) in patients with significant CAD (n = 81). In ROC analysis, area under curve (AUC) for predicting significant CAD in patients of CSAP was better for normalized MAD (0.88) compared to average MAD (4 segment, 0.85).The optimal cutoff of normalized MAD and average MAD for detection of significant CAD were ≤15.3% (sensitivity 90.1%, specificity 79.7%) and ≤11.19 (sensitivity 84%, specificity 69.5%), respectively. Normalized MAD showed week inverse correlation with SYNTAX score (−0.24, R2 = 0.058) and Hs CRP (−0.23, R2 = 0.057). Conclusion MAD is a simple and rapid noninvasive diagnostic tool which accurately predicted the presence of significant CAD in patients with CSAP.
- 1 November 2020
- Published by Wiley in Echocardiography
- Vol. 37 (12) , 2010-2017
Diagnostic utility of mitral annular displacement by speckle tracking echocardiography in predicting significant coronary artery disease in suspected chronic stable angina pectoris
Background More than 50% of patients currently referred for coronary angiography (CAG) with suspected chronic stable angina pectoris (CSAP) shows normal or nonobstructive CAD. Mitral annular displacement (MAD) is a function of global shortening deformation of left ventricle (LV) and mirrors sub‐endocardial ischemia in CAD. The aim of this study was to ascertain if MAD can predict the presence of CAD in patient presenting with suspected CSAP. Methods This cross‐sectional study was conducted on patients with suspected CSAP (n = 140) and preserved LV function without apparent wall motion abnormalities during the study period. We excluded patients with prior heart disease (valvular, ischemic), presenting with acute coronary syndrome, arrhythmia, heart failure, and poor imaging. All the patients were subjected to speckle tracking echocardiography (STE) and CAG. Average MAD and normalized MAD were calculated by automated function imaging (AFI), and receiver operating characteristic (ROC) curve was plotted for presence of significant CAD considering CAG as gold standard. Results The results showed that both average MAD (4 segment) and normalized MAD were significantly reduced (P = <.001) in patients with significant CAD (n = 81). In ROC analysis, area under curve (AUC) for predicting significant CAD in patients of CSAP was better for normalized MAD (0.88) compared to average MAD (4 segment, 0.85).The optimal cutoff of normalized MAD and average MAD for detection of significant CAD were ≤15.3% (sensitivity 90.1%, specificity 79.7%) and ≤11.19 (sensitivity 84%, specificity 69.5%), respectively. Normalized MAD showed week inverse correlation with SYNTAX score (−0.24, R2 = 0.058) and Hs CRP (−0.23, R2 = 0.057). Conclusion MAD is a simple and rapid noninvasive diagnostic tool which accurately predicted the presence of significant CAD in patients with CSAP.